Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sage Therapeutics

6.70
+0.10001.52%
Post-market: 6.900.1999+2.98%19:14 EDT
Volume:647.39K
Turnover:4.31M
Market Cap:419.56M
PE:-1.16
High:6.72
Open:6.52
Low:6.44
Close:6.60
Loading ...

SAGE Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview

Reuters
·
26 Apr

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
22 Apr

Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges

TIPRANKS
·
20 Apr

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

Business Wire
·
15 Apr

RBC Raises Price Target on SAGE Therapeutics to $7 From $6, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
03 Apr

US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert

Benzinga
·
27 Mar

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?

Zacks
·
13 Mar

Sage Therapeutics resumed with an Underperform at BofA

TIPRANKS
·
11 Mar

SAGE Therapeutics Announces CMO Resignation and Interim Appointment

TIPRANKS
·
05 Mar

BRIEF-SAGE Therapeutics Announces Research And Development Leadership Transition

Reuters
·
05 Mar

Sage Therapeutics Announces R&D Leadership Transition

THOMSON REUTERS
·
05 Mar

Sage Therapeutics Announces R&D Leadership Transition

Business Wire
·
05 Mar

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey
·
02 Mar

SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial

TIPRANKS
·
13 Feb

SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth

TIPRANKS
·
13 Feb

Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects

TIPRANKS
·
13 Feb

SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges

TIPRANKS
·
13 Feb

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

Zacks
·
13 Feb

Sage Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
13 Feb

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

TIPRANKS
·
12 Feb